相关实验视频

Updated: Jun 28, 2025

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

血清代谢学改善了发生心力衰竭的风险分层

Rafael R Oexner¹, Hyunchan Ahn¹, Konstantinos Theofilatos¹

¹King's College London British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London, UK.

European journal of heart failure

|April 16, 2024

概括

血清代谢学可以预测心力衰竭 (HF) 的风险. 将代谢物数据与临床评分相结合,可以提高预测准确度,为早期HF检测提供潜在的成本效益替代方案.

科学领域:

生物化学生物化学
心血管医学心血管医学
生物标志物发现发现

背景情况:

心力衰竭 (HF) 构成了全球健康负担,影响生活质量,生存率和医疗保健成本.
早期预测和检测HF对于及时干预和改善患者结果至关重要.

研究的目的:

调查血清代谢学预测能力,特别是通过质子核磁共振 (1H-NMR) 光谱测量168种代谢物,用于发生心力衰竭 (HF).
为了比较基于代谢学预测模型的性能与成熟的临床风险评分.

主要方法:

利用了来自68,311名英国生物库参与者的数据,随访时间超过80万人年.
采用Cox对个体代谢物协会的比例危险模型和使用血清代谢学预测HF的弹性网模型.
与预防HF (PCP-HF) 临床风险评分的聚合队列方程进行基准测试.

主要成果:

几种代谢物与发生的HF有独立的关联,即使经过对临床因素的调整.
基于新陈代谢的风险模型显示,当添加到PCP-HF得分时,预测性能得到改善 (例如,Harrell的C指数增加和净重新分类改进).
结合年龄,性别和新陈代谢的模型实现了与现有临床模型相比的预测能力.

结论:

与单独的PCP-HF得分相比,血清代谢显著提高了发生HF风险的预测.
以代谢学为基础的风险评分,使用年龄和性别,提供与临床评分相比较的预测能力,为HF风险评估提供了潜在的可扩展和成本有效的替代方案.

关键词:

生物标志物生物标志物心脏衰竭是因为心脏衰竭.预防预防预防风险预测风险预测查检查查检查查检查血清代谢组的血清代谢组

更多相关视频

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Published on: March 14, 2013

相关概念视频

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...